Trilobio Raises $8M to Deliver Whole Lab Automation for Biologists
Trilobio was founded in 2021 to address the established data quality and reproducibility challenges limiting research efficiency; it is estimated that 77% of biologists cannot reproduce their own or other's research, despite latest advances in laboratory automation tools (1). Trilobio's co-founders, Roya Amini-Naieni and Maximilian Schommer, were named on Forbes' 30 Under 30 list for their contributions to advances in Manufacturing & Industry. To date, the Company has raised over $11 million, including support from Julian Capital, Juniper, Future Labs Capital, 1517 Fund, Alumni Ventures, Angel Squad, Sequel, Nucleus Capital, Gaingels and others, and has deployed its whole laboratory automation platform at leading biology labs across the United States.
This investment will support the expansion of the Trilobio Platform's robotics capabilities and no-code software features, enabling a growing portfolio of purpose-built lab devices and protocols to be integrated into a single, fully automated platform. Leveraging continual advancement and expansion of the Platform, Trilobio is providing an accessible and scalable solution to transform genetic engineering, synthetic biology and life science research processes, enabling scientists at the cutting-edge to execute research reproducibly, rapidly, and accurately.
Roya Amini-Naieni, CEO and Co-Founder at Trilobio, commented: 'Today's research is more collaborative, innovative, and insightful than ever before, and yet has not reached its full potential because of our inability to reliably reproduce, share, and collectively improve experiments. The future of the field depends on affordable new technologies that empower scientists to overcome these obstacles. '
She added: 'Our mission at Trilobio is to redefine the relationship between scientists and the technologies that power their work every single day, enabling new scientific heights to be reached. We are thankful to have the support of a fantastic portfolio of investors who share our vision. It's time for true automation–connecting and fully automating all processes in the modern biology lab and making the dream of walk-away capabilities a reality.'
The Trilobio Platform consists of the foundational robot, the Trilobot, which is fully programmable through Trilobio OS, the intelligent no-code protocol design software. Each Trilobot houses up to eight different interchangeable lab device tools, effectively creating a self-contained lab in a single device, for example grippers, various pipette tools, and a tube cap/de-capper. The Trilobots, which automatically calibrate themselves and plasticware, can be instantly linked together and work collaboratively, enabling a fleet to be adjusted to individual research requirements and scale capacity instantly.
A user's research protocol is entered into Trilobio OS just like writing a lab notebook entry, initiating the software engine to plan and execute all details without further action required and eliminating hours of coding and research design. Trilobio OS determines the optimal execution of the protocol which can be automatically adjusted for speed, cost, or accuracy. In total, the Trilobio Platform is purpose-built to ensure each step of the workflow is reproducible in any other Trilobio-enabled lab, without the need for hardware recalibration or rewrite of protocols. By providing a reliable and standardized approach, the technology streamlines research design and execution time down to minutes from days or even weeks.
'Roya and Max are uniquely qualified to build the future of lab automation given their interdisciplinary expertise in biology and robotics. I've never seen another founding team with this skillset," said Andrew Sather, Partner at Initialized Capital. "Trilobio is a force-multiplier for the Bio Age, empowering scientists to improve our quality of life and move our species forward."
For more information about Trilobio's platform, please visit: https://trilo.bio/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Wawira Njiru's TED Talk Unveils Africa's Blueprint to End Classroom Hunger
NAIROBI, Kenya--(BUSINESS WIRE)--As the UN Food Systems Summit +4 wraps up in Addis Ababa, Wawira Njiru, Founder and CEO of Food4Education, takes the TED stage with a powerful message: Africa is not waiting for answers, it's creating them. In her TED Talk released today [ ], food systems trailblazer Njiru tells the story of how a simple act of care — feeding 25 children in a makeshift kitchen — sparked a bold, locally-led solution now delivering over 500,000 meals every day. Today, Food4Education is the backbone of Kenya's school feeding infrastructure and a blueprint for countries across Africa investing in nutrition, education, and opportunity all at once. 'School feeding isn't charity, it's strategy, it's infrastructure,' said Njiru. 'It's how we nourish children, support farmers, strengthen education, and build systems that last. We've created a sustainable solution that shows Africa isn't just solving its own challenges — we're setting precedents the world can learn from.' Built on public–private partnership, Food4Education combines government co-investment, parent contributions, and philanthropic force to power its industry-redefining solution. Its green kitchens run on clean energy. Its meals are sourced from local smallholder farmers. Its systems are digital, dignified, and built for scale, with every plate powering learning, livelihoods, and long-term opportunity. Taking the stage as part of The Audacious Project 2024's cohort, Njiru's TED Talk comes at a time of renewed global attention on school feeding as a proven lever for inclusive, sustainable development. With Africa home to the youngest population on Earth, and 1 in 4 people projected to be African by 2050, how the continent feeds its children today will shape the future we all share. 'There's no debate: school meals are among the most effective, scalable tools to strengthen food systems, linking education, nutrition, agriculture, and local economies,' said Shalom Ndiku, Director of Public Affairs at Food4Education. 'At UNFSS+4, it was a proud moment for our whole team to see our work recognized as a flagship intervention in Kenya's national report. It's a testament to the collective effort driving sustainable, African-led school feeding systems.' This is not just a Kenyan story. It's a global opportunity. This TED milestone reflects a growing movement and global recognition that African solutions, grown and led locally, can transform systems at scale. TED2025's theme, Humanity Reimagined, celebrates bold ideas redefining the future. Njiru's TED Talk, From Origin to Opportunity, reframes hunger through three bold provocations: School meals are infrastructure. Hunger, education, and opportunity are interconnected. Feeding children well powers learning, health, and livelihoods all at once. Locally-led solutions work. Food4Education grew from 25 meals to 500,000 a day by investing in African ingenuity, community ownership, and public partnership. Africa can lead the way. With 1 in 4 people projected to be African by 2050, the systems we build on the continent today will shape the world tomorrow. Watch the TED Talk: Understand the depth and impact of Food4Education's work and engage with the vision About Food4Education Hungry kids can't learn or grow. Food4Education is an award-winning, locally rooted, and African-led solution to end classroom hunger. Building on more than a decade of learning by doing, we're powering a new school feeding industry and sharing our blueprint to scale sustainable, nutritious, and affordable school feeding programs across Africa. Today, we serve half a million kids DAILY in Kenya. But every day, we deliver more than a meal — improving nutrition and education outcomes for children while also creating jobs and opportunities for whole communities. We are an experienced and trusted non-profit partner that operates with the excellence of a global business, reinvesting the value we create into local economies. To learn more, please visit
Business Wire
an hour ago
- Business Wire
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. ('Kissei') to develop and commercialize veligrotug and VRDN-003 in Japan. Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies for the potential treatment of patients with thyroid eye disease (TED), and VRDN-003 is a potential best-in-class, subcutaneous, half-life extended anti-IGF-1R antibody with the same binding domain as veligrotug. TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye, often causing swelling, discomfort, and double vision, among other signs and symptoms. 'After running a very competitive partnering process, we are thrilled to partner with Kissei to bring these potential best-in-class medicines to TED patients in Japan,' said Steve Mahoney, Viridian's President and CEO. 'Kissei has an established strong track record of successfully developing and commercializing in-licensed, rare disease medicines. Kissei shares our enthusiasm and commitment to these programs, and we believe Kissei is an ideal partner for us in Japan. Both companies look forward to moving quickly to advance these novel treatment options for patients.' 'As we seek to further expand our pipeline in rare and intractable diseases, we are very excited by the potential of veligrotug and VRDN-003 to address the significant unmet needs of TED patients in Japan, based on veligrotug's strong and consistent phase 3 clinical data in THRIVE and THRIVE-2,' said Mutsuo Kanzawa, Chairman and CEO of Kissei. 'This collaboration reinforces our mission to contribute to the health of people around the world through innovative pharmaceutical products, and we are committed to bringing important treatment options to Japanese patients as rapidly as possible.' Under the terms of the agreement, Viridian will grant Kissei an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan. Viridian will receive an upfront cash payment of $70 million, with the potential to receive an additional $315 million in development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales in Japan with percentages ranging from the 20s to mid-30s. Kissei will be responsible for all development, regulatory, and commercialization activities, and associated costs, in Japan. Renexes LLC served as an advisor to Viridian in connection with the transaction. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X. About Kissei Pharmaceutical Co., Ltd. Kissei is a Japanese pharmaceutical company based on the management philosophy 'contributing to society through high-quality, innovative pharmaceutical products' and 'serving society through our employees.' As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide. Kissei is engaged in bringing new drugs into the world through drug discovery and licensing activities in its focus fields of rare/intractable diseases, urology, and nephrology/dialysis. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, 'anticipate,' 'believe,' 'become,' 'continue,' 'could,' 'design,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'on track,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: Viridian's partnership with Kissei; Viridian's ability to achieve development, regulatory, and commercial milestone payments and receive royalties on the commercial sale of our product candidates pursuant to the agreement with Kissei; clinical development and anticipated commercialization of Viridian's product candidates, including veligrotug (formerly VRDN-001) and VRDN-003; the potential utility, efficacy, potency, safety, clinical benefits, clinical response, convenience, and number of indications of veligrotug and VRDN-003; Viridian's product candidates potentially being best-in-class; whether veligrotug and VRDN-003 will serve an unmet need; and Viridian's expectations regarding the potential commercialization of veligrotug and VRDN-003, if approved, including under the agreement with Kissei. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of Viridian's product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; expectations and changes regarding the timing for regulatory filings; regulatory interactions; uncertainty and potential delays related to clinical drug development; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; competition from other therapies or products; estimates of market size; our future operating results and financial performance; Viridian's intellectual property position; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the 'Risk Factors' section of our filings with the Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date hereof.
Business Wire
an hour ago
- Business Wire
Piraeus Financial Holdings: First Half 2025 Financial Results
ATHENS, Greece--(BUSINESS WIRE)--Piraeus Financial Holdings (ATHEX: TPEIR) (OTCQX: BPIRY) (OTCQX: BPIRF): H1.25 continues our track record of delivering strong results H1 2025 highlights Outstanding loan book and client assets growth Loans at €36bn, up €2.2bn in H1 and 15% yoy, already meeting the target for end-2025; We upgrade full year target to >€36.5bn loans. €6.3bn new loans disbursed in the Greek economy since the beginning of the year, marking our best first half performance on record; Credit expansion supported by all business lending segments; household lending increased +€70mn in Q2 Client assets under management (AuM) increased by 27% yoy, at €13.2bn, surpassing the full-year target of >€12.0bn; We upgrade our target to >€13.5bn assets under management for end-2025 Sustainable profits and returns Solid profitability of €559mn in H1, corresponding to €0.43 earnings per share, well on track to meet the full year target of c.€0.80; 15% return on tangible book value, compared to c.14% target for the full year; tangible book value per share increased to €5.90, up 8% yoy Net revenues at €687mn in Q2, up by 6% qoq, due to resilient NII, good performance in fees and trading income; NII dropped by 1.5% qoq, compared to -6% in Q1, despite steep decline in rates Net fee income in H1 was stable yoy, at 24% over net revenue Piraeus intends to proceed to an interim distribution out of 2025 profit, amounting to €100mn in the form of share buyback, to be executed during fourth quarter 2025, subject to the necessary supervisory and EGM approvals Discipline in operating efficiency and balance sheet management Operating efficiency, with 34% cost-to-core-income ratio in H1, among the best across EU banks, while continuing to invest in our people, technology and business growth Strong balance sheet, with organic cost of risk at 0.5%, in line with the full year target. NPE ratio at 2.6% vs. 3.3% a year ago and prudent NPE coverage at 67%, up 9 percentage points yoy Superior liquidity profile with €63bn deposits (+5% yoy) and liquidity coverage ratio at 206% CET1 with comfortable buffers above management target Pro forma CET1 ratio stood at 14.4% and total capital ratio at 20.4%, absorbing the 50% distribution accrual for 2025, robust loan growth and DTC amortization Buffer of approximately 440bps above P2G (16.0%) Aspiration for above €500mn total distribution out of 2025 profits
